AEMD AETHLON MEDICAL INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 882291 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY28.3%
TTM EPS YoY137.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-136.8%
ROA-110.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets17.4%
Debt / equity0.00x
Current ratio5.37x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q22026-09-30 | 2027Q12026-06-30 | 2026Q4*2026-03-31 | 2026Q32025-12-31 | 2026Q22025-09-30 | 2026Q12025-06-30 | 2025Q4*2025-03-31 | 2025Q32024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $481,000 | $549,000 | $589,984 | $532,782 | $294,000 | $524,000 | $1.33M | $240,199 |
| SG&A expense | $682,477 | $662,450 | $698,016 | $741,650 | $521,423 | $735,358 | $717,961 | $816,383 |
| Operating income | -$2.68M | -$1.58M | -$1.93M | -$2.06M | -$1.51M | -$1.79M | -$2.00M | -$1.81M |
| Net income | -$2.62M | -$1.55M | -$1.88M | -$2.02M | -$1.49M | -$1.76M | -$6.25M | -$1.75M |
| EBITDA | -$2.59M | -$1.51M | -$1.85M | -$1.98M | -$1.43M | -$1.71M | -$1.92M | -$1.73M |
| EPS (basic) | -2.60 | -4.02 | — | -2.45 | -18.70 | -42.42 | — | -10.05 |
| EPS (diluted) | -2.60 | -4.02 | — | -2.45 | -18.70 | -42.42 | — | -10.05 |
| Weighted avg. shares (diluted) | 1.01M | 384,705 | — | 823,126 | 79,503 | 41,529 | — | 174,529 |
| Banking | ||||||||
| Net interest income | $54,001 | $31,290 | — | $43,871 | $22,730 | $30,532 | — | $59,964 |
| Balance sheet | ||||||||
| Cash & equivalents | $6.49M | $4.93M | $5.03M | $6.96M | $5.85M | $3.77M | $5.60M | $4.83M |
| Current assets | $6.86M | $5.61M | $5.57M | $7.14M | $6.25M | $4.05M | $5.95M | $4.97M |
| PP&E, net | $215,126 | $293,112 | $356,822 | $434,179 | $513,992 | $593,720 | $676,220 | $762,138 |
| Intangibles | — | — | $0 | $138 | $275 | $413 | $550 | $688 |
| Total assets | $7.33M | $6.24M | $6.33M | $8.06M | $7.32M | $5.31M | $7.36M | $6.53M |
| Current liabilities | $1.28M | $1.04M | $1.45M | $1.26M | $1.40M | $1.63M | $1.90M | $1.77M |
| Total liabilities | $1.28M | $1.04M | $1.45M | $1.34M | $1.58M | $1.88M | $2.24M | $2.19M |
| Shareholders' equity | $6.05M | $5.20M | $4.89M | $6.71M | $5.75M | $3.42M | $5.12M | $4.33M |
| Shares outstanding | 1.61M | 477,402 | 314,100 | 973,213 | 761,318 | 2.60M | 201,074 | 13.99M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.74M | -$1.90M | -$1.75M | -$1.87M | -$1.66M | -$1.71M | -$1.67M | -$2.01M |
| Capital expenditure | $2,165 | $9,150 | $2,051 | $1,653 | $0 | $0 | -$2,192 | $2,192 |
| Free cash flow | -$1.74M | -$1.91M | -$1.75M | -$1.88M | -$1.66M | -$1.71M | -$1.67M | -$2.01M |
| Investing cash flow | -$2,165 | -$9,150 | -$2,051 | -$1,653 | $0 | $0 | $2,192 | -$2,192 |
| Financing cash flow | $3.29M | $1.82M | -$196,496 | $2.98M | $3.74M | -$5,357 | $2.36M | -$7,073 |
| Depreciation & amortization | $80,150 | $72,860 | $79,547 | $81,603 | $79,866 | $82,637 | $83,864 | $83,808 |
| Stock-based compensation | $50,000 | $50,000 | $61,221 | $72,442 | $72,442 | $72,442 | $72,443 | $89,970 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.